Exact Sciences Corp at Cowen HealthCare Conference Transcript
All right. Good afternoon. It's our pleasure to welcome Jeff Elliott and Megan Jones from Exact Sciences to the 40th Annual Cowen Health Care Conference. Exact Sciences is our tough larger cap growth pick for 2020. The company's Cologuard test is targeting an annual revenue opportunity of $17 billion.
There's a promising pipeline and the recent acquisition of Genomic Health, as not just the market-leading Oncotype test for predicting chemo benefit in breast cancer patients, but a platform for global growth and precision oncology, both organically and inorganically.
So Jeff, thanks for being here. We have a pretty aggressive list of topics to cover over the next 29 minutes. So thanks for being here. And now we'll get into that.
I think that's it.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
